Monographs: Dosage forms: Specific monographs: Capreomycin for injection (Capreomycini ad injectionem)

[Note from the Secretariat. The user should note that the monograph describes a chromatographic assay to determine the mass concentrations of capreomycin IA, IB, IIA and IIB in a sample under investigation. These concentrations should comply with the requirements set out under the heading “Definition”. The finished product also has to be tested with a suitably validated microbiological assay method and the obtained result has to comply with appropriate limits for the activity of capreomycin. A correlation between the mass concentrations of IA, IB, IIA and IIB and the activity of the substance, determined with microbiological methods, has not been established during the elaboration of the monograph.]

Description. A white or almost white powder.

Category. Antituberculosis drug.

Storage. Capreomycin for injection should be stored in a well-closed container.

Labelling. The designation on the container of capreomycin for injection should state that the active ingredient is in the sulfate form and the quantity should be indicated in terms of the equivalent amount of capreomycin.

Additional information. The injection is reconstituted by dilution of Capreomycin powder for injections in Water for injections.

The reconstituted injection should be used immediately after preparation.

Requirements

The powder for injection and the reconstituted injection comply with the monograph for Parenteral Preparations.

Definition. Capreomycin for injection is a sterile powder containing Capreomycin sulfate. It contains not less than 90.0% and not more than 115.0% of the amount of capreomycin stated on the label, taking into account the sum of capreomycin IA, IB, IIA and IIB.

Identity tests

  • Either tests A, B and F or tests C, D, E and F may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from capreomycin sulfate for identification RS or with the reference spectrum of capreomycin sulfate.

B. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography using silica gel R5 as the coating substance and a mixture of 30 volumes of phenol R, 10 volumes of water R and 1 volume of ammonia (~260 g/L) TS as the mobile phase. Apply separately to the plate 4 μL of each of the following two solutions in water R. For solution (A) dissolve a quantity of the powder to obtain a solution containing 10 mg of the powder for injection per mL. For solution (B) use 10 mg of capreomycin sulfate for identification RS per mL. After removing the plate from the chromatographic chamber allow it to dry exhaustively in air. Spray with triketohydrindene/methanol TS and heat the plate for 3 minutes at 120 °C. Examine the chromatogram in daylight.

The spots obtained with solution A correspond in position, appearance and intensity with those obtained with solution B.

C. Carry out the test as described under 1.14.4 High performance liquid chromatography using the conditions and solutions given under “Assay”. The retention times of the four major peaks in the chromatogram obtained with solution (1) correspond to the retention times of the peaks due to capreomycin IA, IB, IIA and IIB in the chromatogram obtained with solution (2).

D. Dissolve a quantity of the powder for injection in hydrochloric acid (0.1 mol/L) VS to obtain a solution containing the equivalent of 20 µg of capreomycin per mL. The absorption spectrum (1.6) of this solution, when observed between 230 nm and 350 nm, exhibits a maximum at about 268 nm.

E. Dissolve a quantity of the powder for injection in sodium hydroxide (0.1 mol/L) VS to obtain a solution containing the equivalent of 20 µg of capreomycin per mL. The absorption spectrum (1.6) of this solution, when observed between 230 nm and 350 nm, exhibits a maximum at about 287 nm.

F. A solution of the powder for injection containing the equivalent of 20 mg of capreomycin per mL yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

Clarity of solution. A freshly prepared solution of the powder for injection containing the equivalent of 1 g of capreomycin in 10 mL of carbon-dioxide-free water R is clear.

pH value (1.3). pH of a solution of the powder for injection containing the equivalent of 0.3 g of capreomycin in 10 mL of carbon-dioxide-free water R, 4.5–7.5.

Bacterial endotoxins. Carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 0.35 IU of endotoxin per mg of capreomycin.

Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”.

Prepare the following solutions using Mobile phase A as diluent. For solution (1) dissolve a quantity of the powder for injection to obtain a solution containing the equivalent of 2.0 mg of capreomycin per mL. For solution (2) dilute a suitable volume of solution (1) to obtain a concentration of 10 µg of capreomycin per mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 268 nm.

Inject 20 μL of solution (1). The test is not valid unless the resolution between the two major peaks corresponding to capreomycin IA (with a relative retention of about 0.89) and capreomycin IB (retention time about 38 minutes) is at least 2.0 and the resolution between the peaks corresponding to capreomycin IIA and capreomycin IIB (with a relative retention of 0.53 and 0.63, respectively) is at least 3.5.

Inject separately 20 μL each of solutions (1) and (2).

In the chromatogram obtained with solution (1):

  • the area of any peak, other than the four major peaks corresponding to capreomycin IA, IB, IIA and IIB, is not greater than 4 times the sum of the areas of the four major peaks obtained with solution (2) (2.0%);
  • the area of not more than one such peak is greater than twice the sum of the areas of the four major peaks obtained with solution (2) (1.0%);
  • the sum of the areas of all peaks, other than the four major peaks, is not greater than 14 times the sum of the areas of the four major peaks obtained with solution (2) (7.0%). Disregard any peak with an area less than 0.1 times the sum of the areas of the four major peaks in the chromatogram obtained with solution (2) (0.05%).

Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm x 4.6 mm) packed with base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 μm).

The mobile phases for the gradient elution consist of a mixture of mobile phase A and mobile phase B using the following conditions:

mobile phase A: 5 volumes of acetonitrile R and 95 volumes of phosphate buffer pH 2.3;

mobile phase B: 15 volumes of acetonitrile R and 85 volumes of phosphate buffer pH 2.3.

Prepare the phosphate buffer pH 2.3 by dissolving 54.4 g of potassium dihydrogen phosphate R in 1500 mL of water R, adjust the pH to 2.3 by adding phosphoric acid (~105 g/L) TS, add 9.4 g of sodium hexanesulfonate R and dilute to 2000 mL with water R.

Time

(min)

Mobile phase A

(% v/v)

Mobile phase B

(% v/v)

Comments

0–25

55–52

45–48

Linear gradient

25–40

52

48

Isocratic

40–60

30

70

Isocratic

60–70

55

45

Isocratic re-equilibration

Weigh and mix the contents of 5 containers. Prepare the following solutions using mobile phase A as diluent. For solution (1) dissolve a quantity of the mixed contents, containing the equivalent of 80.0 mg of capreomycin and dilute to 50.0 mL. For solution (2) dissolve the content of a vial of capreomycin sulfate RS in 5.0 mL.

Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 268 nm.

Inject 20 μL of solution (1). The assay is not valid unless the resolution between the two major peaks corresponding to capreomycin IA (with a relative retention of 0.89) and capreomycin IB (retention time about 38 minutes) is at least 2.0 and the resolution between the peaks corresponding to capreomycin IIA and capreomycin IIB (with a relative retention of 0.53 and 0.63, respectively) is at least 3.5.

Inject separately 20 μL each of solutions (1) and (2).

Measure the areas of the peak responses for capreomycin IA, IB, IIA and IIB obtained in the chromatograms from solutions (1) and (2) and, using the sum of the areas, calculate the percentage content of capreomycin per sealed container using the declared content in capreomycin sulfate RS.

to previous sectionto next section